A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
← catalyst calendarNCT04844606 · readout ≤ 1,595 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
150estimated
Sites
68
Countries
Austria, Belgium, Brazil +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-26 | actual | When the study began enrolling |
| Primary completion | Dec 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2021-04-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ulcerative Colitis
- Ulcerative Colitis Chronic
- Inflammatory Bowel Diseases
- Crohn's Disease
Interventions
- Drug: Mirikizumab — also filed as LY3074828
- Drug: Mirikizumab — also filed as LY3074828
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants with UC in Modified Mayo Score (MMS) Clinical Remission
measured Week 52
Percentage of Participants with CD in Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission
measured Week 52
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed